Rhythm Pharma (RYTM) added ~15% on Thursday after the company announced plans to advance its lead asset, setmelanotide, into a registrational Phase 3 trial for a rare genetic disorder called Prader-Willi syndrome following a promising mid-stage readout.
Characterized by an